Skip to main content

Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era.

Experimental hematology & oncology

Authors: Tingting Zhang, Weiwei Tian, Shuang Wei, Xinyi Lu, Jing An, Shaolong He, Jie Zhao, Zhilin Gao, Li Li, Ke Lian, Qiang Zhou, Huilai Zhang, Liang Wang, Liping Su, Huicong Kang, Ting Niu, Ailin Zhao, Jing Pan, Qingqing Cai, Zhenshu Xu, Wenming Chen, Hongmei Jing, Peng Li, Wanhong Zhao, Yang Cao, Jianqing Mi, Tao Chen, Yuan Chen, Ping Zou, Veronika Lukacs-Kornek, Christian Kurts, Jian Li, Xiansheng Liu, Qi Mei, Yicheng Zhang, Jia Wei

The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.

© 2023. The Author(s).

PMID: 37501090

Participating cluster members